COSMOS Pharmaceutical Corporation (3349.T)

9053.0035.00 (-0.39%)

COSMOS Pharmaceutical Corporation (3349.T) stock comprehensive Income Growth Analysis including revenue, gross profit, operating profit, net profit, EPS, and other financial metrics. Compare income growth against peers/competitors, industry and sector standards.

Low Bankruptcy RiskLow ProfitabilityEfficient OperationsModerate GrowthModerate QualityAdequate Dividend ProfileIndustry Rank: 67.57%Sector Rank: 75.68%

JPX - Healthcare - Medical - Pharmaceuticals | Market Cap: 717.52B | Next Earnings Date: 14 Oct 2025

Day's Range

8935.00 - 9125.00

52-Week Range

6347.00 - 10045.00

Volume

380.0K / 335.9K (Avg.)

P/E Ratio | EPS

23.15 | 391.09

Trending:

3349.T Income Growth Analysis

Compare against a Competitor

None 3391.T 3141.T 3088.T 2127.T 9843.T

Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.

Revenue Growth

4.28%

Decreased from previous period

Growth of 4.28% versus flat Healthcare revenue. Walter Schloss would verify growth quality.

Cost of Revenue Growth

4.39%

Decreased from previous period

Cost growth of 4.39% versus flat Healthcare costs. Walter Schloss would verify cost control.

Gross Profit Growth

3.84%

Decreased from previous period

Growth of 3.84% versus flat Healthcare gross profit. Walter Schloss would verify quality.

Gross Margin Ratio Growth

-0.42%

Decreased from previous period

Margin decline while Healthcare median is 0.00%. Seth Klarman would investigate competitive position.

R&D Expenses Growth

No Data

No Data available this quarter, please select a different quarter.

G&A Expenses Growth

-100.00%

G&A reduction while Healthcare median is 0.00%. Seth Klarman would investigate efficiency gains.

Selling & Marketing Expenses Growth

-100.00%

Marketing expense reduction while Healthcare median is 0.00%. Seth Klarman would investigate competitive implications.

Other Expenses Growth

-12.24%

Decreased from previous period

Other expenses reduction while Healthcare median is 0.00%. Seth Klarman would investigate advantages.

Operating Expenses Growth

4.92%

Increased from previous period

Operating expenses change of 4.92% versus flat Healthcare costs. Walter Schloss would verify control.

Total Costs & Expenses Growth

4.48%

Increased from previous period

Total costs change of 4.48% versus flat Healthcare costs. Walter Schloss would verify control.

Interest Expense Growth

-9.09%

Decreased from previous period

Interest expense reduction while Healthcare median is 0.00%. Seth Klarman would investigate advantages.

Depreciation & Amortization Growth

-12.21%

Decreased from previous period

D&A reduction while Healthcare median is 0.00%. Seth Klarman would investigate efficiency.

EBITDA Growth

-0.77%

Decreased from previous period

EBITDA decline while Healthcare median is 0.00%. Seth Klarman would investigate causes.

EBITDA Margin Growth

-4.85%

Decreased from previous period

EBITDA margin decline while Healthcare median is 0.00%. Seth Klarman would investigate causes.

Operating Income Growth

0.34%

Decreased from previous period

Income change of 0.34% versus flat Healthcare. Walter Schloss would verify quality.

Operating Margin Growth

-3.78%

Decreased from previous period

Operating margin decline while Healthcare median is 0.00%. Seth Klarman would investigate causes.

Other Income/Expenses Growth

-70.13%

Decreased from previous period

Other expenses reduction while Healthcare median is 5.26%. Seth Klarman would investigate advantages.

Pre-Tax Income Growth

-5.55%

Decreased from previous period

Pre-tax income decline while Healthcare median is 0.00%. Seth Klarman would investigate causes.

Pre-Tax Margin Growth

-9.43%

Decreased from previous period

Pre-tax margin decline while Healthcare median is 0.00%. Seth Klarman would investigate causes.

Income Tax Expense Growth

24.46%

Increased from previous period

Tax expense change of 24.46% versus flat Healthcare. Walter Schloss would verify strategy.

Net Income Growth

-15.18%

Decreased from previous period

Net income decline while Healthcare median is 0.00%. Seth Klarman would investigate causes.

Net Margin Growth

-18.66%

Decreased from previous period

Net margin decline while Healthcare median is 0.00%. Seth Klarman would investigate causes.

EPS Growth

-15.18%

Decreased from previous period

EPS decline while Healthcare median is 0.00%. Seth Klarman would investigate causes.

Diluted EPS Growth

-15.18%

Decreased from previous period

Diluted EPS decline while Healthcare median is 0.00%. Seth Klarman would investigate causes.

Share Count Growth (Basic)

0.00%

Share count reduction exceeding 1.5x Healthcare median of 0.09%. Joel Greenblatt would investigate strategy.

Share Count Growth (Diluted)

No Data

No Data available this quarter, please select a different quarter.

Select Chart Metric:

3349.T Income Growth Analysis

Compare against a Competitor

None 3391.T 3141.T 3088.T 2127.T 9843.T

Revenue Growth

4.28%

Decreased from previous period

Growth of 4.28% versus flat Healthcare revenue. Walter Schloss would verify growth quality.

Cost of Revenue Growth

4.39%

Decreased from previous period

Cost growth of 4.39% versus flat Healthcare costs. Walter Schloss would verify cost control.

Gross Profit Growth

3.84%

Decreased from previous period

Growth of 3.84% versus flat Healthcare gross profit. Walter Schloss would verify quality.

Gross Margin Ratio Growth

-0.42%

Decreased from previous period

Margin decline while Healthcare median is 0.00%. Seth Klarman would investigate competitive position.

R&D Expenses Growth

No Data

No Data available this quarter, please select a different quarter.

G&A Expenses Growth

-100.00%

G&A reduction while Healthcare median is 0.00%. Seth Klarman would investigate efficiency gains.

Selling & Marketing Expenses Growth

-100.00%

Marketing expense reduction while Healthcare median is 0.00%. Seth Klarman would investigate competitive implications.

Other Expenses Growth

-12.24%

Decreased from previous period

Other expenses reduction while Healthcare median is 0.00%. Seth Klarman would investigate advantages.

Operating Expenses Growth

4.92%

Increased from previous period

Operating expenses change of 4.92% versus flat Healthcare costs. Walter Schloss would verify control.

Total Costs & Expenses Growth

4.48%

Increased from previous period

Total costs change of 4.48% versus flat Healthcare costs. Walter Schloss would verify control.

Interest Expense Growth

-9.09%

Decreased from previous period

Interest expense reduction while Healthcare median is 0.00%. Seth Klarman would investigate advantages.

Depreciation & Amortization Growth

-12.21%

Decreased from previous period

D&A reduction while Healthcare median is 0.00%. Seth Klarman would investigate efficiency.

EBITDA Growth

-0.77%

Decreased from previous period

EBITDA decline while Healthcare median is 0.00%. Seth Klarman would investigate causes.

EBITDA Margin Growth

-4.85%

Decreased from previous period

EBITDA margin decline while Healthcare median is 0.00%. Seth Klarman would investigate causes.

Operating Income Growth

0.34%

Decreased from previous period

Income change of 0.34% versus flat Healthcare. Walter Schloss would verify quality.

Operating Margin Growth

-3.78%

Decreased from previous period

Operating margin decline while Healthcare median is 0.00%. Seth Klarman would investigate causes.

Other Income/Expenses Growth

-70.13%

Decreased from previous period

Other expenses reduction while Healthcare median is 5.26%. Seth Klarman would investigate advantages.

Pre-Tax Income Growth

-5.55%

Decreased from previous period

Pre-tax income decline while Healthcare median is 0.00%. Seth Klarman would investigate causes.

Pre-Tax Margin Growth

-9.43%

Decreased from previous period

Pre-tax margin decline while Healthcare median is 0.00%. Seth Klarman would investigate causes.

Income Tax Expense Growth

24.46%

Increased from previous period

Tax expense change of 24.46% versus flat Healthcare. Walter Schloss would verify strategy.

Net Income Growth

-15.18%

Decreased from previous period

Net income decline while Healthcare median is 0.00%. Seth Klarman would investigate causes.

Net Margin Growth

-18.66%

Decreased from previous period

Net margin decline while Healthcare median is 0.00%. Seth Klarman would investigate causes.

EPS Growth

-15.18%

Decreased from previous period

EPS decline while Healthcare median is 0.00%. Seth Klarman would investigate causes.

Diluted EPS Growth

-15.18%

Decreased from previous period

Diluted EPS decline while Healthcare median is 0.00%. Seth Klarman would investigate causes.

Share Count Growth (Basic)

0.00%

Share count reduction exceeding 1.5x Healthcare median of 0.09%. Joel Greenblatt would investigate strategy.

Share Count Growth (Diluted)

No Data

No Data available this quarter, please select a different quarter.

Select Chart Metric: